COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,400 Articles (22,816 medRxiv, 8,584 bioRxiv)

Most recent first Previous |  Page 1633: Articles 16321-16330  | Next

Reliability of Spike Gene Target Failure for ascertaining SARS-CoV-2 lineage B.1.1.7 prevalence in a hospital setting
Guerra-Assuncao, J. A., Randell, P. A., Boshier, F. A. T., Crone, M. A., Pang, J., Mahungu, T. W., Freemont, P., Breuer, J.
10.1101/2021.04.12.21255084 — Posted: 2021-04-14
One-Seq: A Highly Scalable Sequencing-Based Diagnostic for SARS-CoV-2 and Other Single-Stranded Viruses
Dai, M., Ma, W., Kang, H., Sonnett, M., Church, G. M., Kirschner, M. W.
10.1101/2021.04.12.21253357 — Posted: 2021-04-14
Effect of COVID-19 on Lipid Profile and its Correlation with Acute Phase Reactants
Malik, J., Ishaq, U., Laique, T., Ashraf, A., Malik, A., Rathore, M. A., Zaidi, S. M. J., Javaid, M., Mehmood, A.
10.1101/2021.04.13.21255142 — Posted: 2021-04-14
Rapid spread and high impact of the Variant of Concern P.1 in the largest city of Brazil
Barbosa, G., Moreira, L. V. L., Justo, A. F. O., Perosa, A. H., Chaves, A. P., Bueno, M. S., de Souza Luna, L. K., Conte, D. D., Carvalho, J. M., Prates, J., Dantas, P. S., Faico, K., Camargo, C., Resende, P. C., Siqueira, M., Bellei, N. c. j.
10.1101/2021.04.10.21255111 — Posted: 2021-04-14
Behavioral nudges increase COVID-19 vaccinations: Two randomized controlled trials
Dai, H., Saccardo, S., Han, M. A., Roh, L., Raja, N., Vangala, S., Modi, H., Pandya, S., Croymans, D. M.
10.1101/2021.04.12.21254876 — Posted: 2021-04-14
Occupational risks of COVID-19 in NHS workers in England
van der Plaat, D., Madan, I., Coggon, D., van Tongeren, M., Edge, R., Muiry, R., Parsons, V., Cullinan, P.
10.1101/2021.04.08.21255099 — Posted: 2021-04-14
You're just there, alone in your room with your thoughts: A qualitative study about the impact of lockdown among young people during the COVID-19 pandemic
McKinlay, A. R., May, T., Dawes, J., Fancourt, D., Burton, A.
10.1101/2021.04.11.21254776 — Posted: 2021-04-14
An mRNA SARS-CoV-2 vaccine employing a novel delivery vehicle with a TLR-9 agonist induces neutralizing antibodies and T cell memory
Haabeth, O., Lohmeyer, J., Sallets, A., Blake, T., Sagiv-Barfi, I., Czerwinski, D., Powell, A. E., Wender, P. A., Waymouth, R. M., Levy, R.
10.1101/2021.04.14.439891 — Posted: 2021-04-14
INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
Andrade, V. M., Christensen-Quick, A., Agnes, J., Tur, J., Reed, C., Kalia, R., Marrero, I., Elwood, D., Schultheis, K., Purwar, M., Reuschel, E., McMullan, T., Pezzoli, P., Kraynyak, K., Sylvester, A., Mammen, M. P., Tebas, P., Kim, J. J., Weiner, D. B., Smith, T. R., Ramos, S. J., Humeau, L. M., Boyer, J. D., Broderick, K. E.
10.1101/2021.04.14.439719 — Posted: 2021-04-14
Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots
Verkhivker, G. M., Agajanian, S., Oztas, D. Y., Gupta, G.
10.1101/2021.04.13.439743 — Posted: 2021-04-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).